Overview

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant patients with noncancer-related chronic pain.

Phase:

Phase 3

Details

Lead Sponsor:

Cephalon

Treatments:

Citric Acid
Fentanyl